Alnylam Pharmaceuticals (NASDAQ:ALNY) Q4 results:
Total revenues: $71.7M (+241.4%); Onpattro sales: $55.8M (+361.2%); collaborator revenue: $15.7M (+74.4%).
Collaborator revenue primarily from Regeneron partnership.
Givlaari: 13 start forms submitted. Initial sales of $0.2M represented initial channel stocking.
Net loss: ($221.3M); loss/share: ($2.47).
2020 guidance: Onpattro sales: $285M – 315M; collaborator revenue: $100M – 150M.
https://seekingalpha.com/news/3539198-q4-sales-of-alnylams-onpattro-up-361
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.